SCHEMBL4625490

SCHEMBL4625490

CC(C)(C)C(Cc1ccc2nc(-c3c(Cl)cccc3Cl)ccc2c1)(NC(=O)c1c(Cl)cccc1Cl)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 9/20 0.59
ITGAV P06756 1/20 0.59
ABL1 P00519 1/20 0.38
ITGA4 P13612 7/20 0.38
ITGB7 P26010 3/20 0.38
KMT2A Q03164 1/20 0.35
EGLN3 Q9H6Z9 1/20 0.33
PTGFR P43088 3/20 0.32
FFAR1 O14842 1/20 0.32
ITGA5 P08648 1/20 0.32
KCNH2 Q12809 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
GHSR Q92847 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3319930 0.88 ITGB1 (0.61) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL1028112 0.83 ITGB1 (0.55) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL4624872 0.80 ITGB1 (0.51) ITGB1ITGAVITGA4ITGB7GHSR
SCHEMBL4626504 0.79 ITGB1 (0.53) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL4750015 0.79 ITGB1 (0.53) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL3313216 0.79 ITGB1 (0.50) ITGB1ITGAVABL1ITGA4ITGB7
SCHEMBL1030228 0.77 ITGB1 (0.49) ITGB1ITGAVABL1HRH3ALDH1A1
SCHEMBL4747267 0.75 ITGB1 (0.47) ITGB1ITGAVABL1
SCHEMBL3313373 0.74 ITGB1 (1.00) ITGB1ITGAVITGA4ITGB7ITGA5
SCHEMBL3316398 0.74 ITGB1 (1.00) ITGB1ITGAVITGA4ITGB7ITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP disclosed
EP-1870402-A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors UCB Pharma, S.A. (BE) 2007-12-26 EP disclosed